High-dose pulse chlorambucil. Effective therapy for rapid remission induction in nodular lymphocytic poorly differentiated lymphoma
✍ Scribed by Ed Cadman; Frank Drislane; James A. Waldron Jr.; Leonard Farber; Leonard Prosnitz; Joseph R. Bertino
- Book ID
- 101326096
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 465 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Eighteen patients with Stage I11 or IV nodular poorly differentiated lymphocytic lymphoma (malignant lymphoma, infiltrative nodular type, with predominately small cleaved cells) were treated with intermittent high-dose oral chlorambucil(16 mg/m2 daily for five consecutive days each month) for one year. Complete clinical remissions occurred in 78% of these patients and partial remissions in another 17%. Complete remission usually occurred within three months of beginning therapy and with a median followup of 35 months no patient has relapsed. Toxicity, usually hematologic and occurring late in therapy, has been mild, necessitating termination of therapy in only one patient. Review of recent therapy fails to demonstrate a definite long-term advantage of more aggressive treatment regimens. Intermittent highdose chlorambucil should be further evaluated as therapy for nodular poorly differentiated lymphocytic lymphoma.